Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials

There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials. We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded, multi-site, randomized trials with rispe...

Full description

Saved in:
Bibliographic Details
Published in:Journal of autism and developmental disorders 2013-03, Vol.43 (3), p.739-746
Main Authors: Scahill, Lawrence, Hallett, Victoria, Aman, Michael G., McDougle, Christopher J., Eugene Arnold, L., McCracken, James T., Tierney, Elaine, Deng, Yanhong, Dziura, James, Vitiello, Benedetto
Format: Article
Language:English
Subjects:
Aberrant Behavior Checklist
Adolescent
Antipsychotic Agents - therapeutic use
Autism
Behavior Problems
Behavior Rating Scales
Behavioral Science and Psychology
Biological and medical sciences
Brief Report
Check Lists
Child
Child and School Psychology
Child clinical studies
Child Development Disorders, Pervasive - drug therapy
Child Development Disorders, Pervasive - psychology
Child, Preschool
Comparative Analysis
Developmental disorders
Double-Blind Method
Drug Use
Effect Size
Humans
Infantile autism
Medical sciences
Neuropharmacology
Neurosciences
Pediatrics
Pervasive Developmental Disorders
Pharmacology
Pharmacology. Drug treatments
Psychiatric Status Rating Scales
Psycholeptics: tranquillizer, neuroleptic
Psychology
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Public Health
Research Design
Risperidone - therapeutic use
Social Behavior
Social Desirability
Social Perception
Treatment Outcome
Withdrawal (Psychology)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials. We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded, multi-site, randomized trials with risperidone. Study 1 included 52 subjects assigned to placebo and 49 subjects to risperidone under double-blind conditions. Study 2 included 49 subjects assigned to risperidone only and 75 subjects assigned to risperidone plus parent training. After 8 weeks of treatment, all active treatments were superior to placebo (effect sizes ranging from 0.42 to 0.65). The findings suggest that the Social Withdrawal subscale may be a useful measure of social disability in acute treatment trials.
ISSN:0162-3257
1573-3432
1573-3432
DOI:10.1007/s10803-012-1689-3